These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 18292709)

  • 1. Response: a case for collaborative care.
    Gonzales R; Perlman DC
    Addict Sci Clin Pract; 2007 Dec; 4(1):43-4. PubMed ID: 18292709
    [No Abstract]   [Full Text] [Related]  

  • 2. Hepatitis C for addiction professionals.
    Sylvestre D
    Addict Sci Clin Pract; 2007 Dec; 4(1):34-41. PubMed ID: 18292708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Referral of intravenous drug users for antiviral treatment: effectiveness of hepatitis C case-finding programmes.
    Gazdag G; Horváth G; Szabó O; Ungvari GS
    Cent Eur J Public Health; 2012 Sep; 20(3):223-5. PubMed ID: 23285525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Screening blood-borne virus among incarcerated inmates.
    Chong VH
    Int J STD AIDS; 2008 Nov; 19(11):795. PubMed ID: 18931282
    [No Abstract]   [Full Text] [Related]  

  • 5. Body composition, gender, and illicit drug use in an urban cohort.
    Cofrancesco J; Brown TT; Luo RF; John M; Stewart KJ; Dobs AS
    Am J Drug Alcohol Abuse; 2007; 33(3):467-74. PubMed ID: 17613974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. European monitoring of notifications of hepatitis C virus infection in the general population and among injecting drug users (IDUs) - the need to improve quality and comparability.
    Wiessing L; Guarita B; Giraudon I; Brummer-Korvenkontio H; Salminen M; Cowan SA
    Euro Surveill; 2008 May; 13(21):. PubMed ID: 18761969
    [No Abstract]   [Full Text] [Related]  

  • 7. Prisons, prisoners, and hepatitis C.
    Ferguson L; Batey R
    J Gastroenterol Hepatol; 2010 Jul; 25(7):1184-6. PubMed ID: 20594243
    [No Abstract]   [Full Text] [Related]  

  • 8. Using latent class analysis to identify patterns of hepatitis C service provision in drug-free treatment programs in the U.S.
    Strauss SM; Rindskopf DM; Astone-Twerell JM; Des Jarlais DC; Hagan H
    Drug Alcohol Depend; 2006 Jun; 83(1):15-24. PubMed ID: 16289523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of opioid addiction in primary care: a pragmatic approach prioritising wellbeing not ideology.
    Lawson E
    Br J Gen Pract; 2013 May; 63(610):231-2. PubMed ID: 23643204
    [No Abstract]   [Full Text] [Related]  

  • 10. Improved hepatitis C screening and treatment in people who inject drugs should be a priority in Europe.
    Kautz A; Chavdarova L; Walker M
    BMC Infect Dis; 2014; 14 Suppl 6(Suppl 6):S3. PubMed ID: 25253094
    [No Abstract]   [Full Text] [Related]  

  • 11. [Treatment of chronic hepatitis C in drug users: ethic, successful and useful].
    Remy AJ; Wenger H; Bouchkira H
    Presse Med; 2014 Dec; 43(12 Pt 1):1314-6. PubMed ID: 25307441
    [No Abstract]   [Full Text] [Related]  

  • 12. [Hepatitis C and drug use: epidemiology, screening, natural history and treatment].
    Lucidarme D
    Gastroenterol Clin Biol; 2002 Apr; 26 Spec No 2():B112-20. PubMed ID: 12180278
    [No Abstract]   [Full Text] [Related]  

  • 13. Hepatitis C management by addiction medicine physicians: results from a national survey.
    Litwin AH; Kunins HV; Berg KM; Federman AD; Heavner KK; Gourevitch MN; Arnsten JH
    J Subst Abuse Treat; 2007 Jul; 33(1):99-105. PubMed ID: 17379472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis C action plan for Scotland: phase II (May 2008-March 2011).
    Goldberg D; Brown G; Hutchinson S; Dillon J; Taylor A; Howie G; Ahmed S; Roy K; King M;
    Euro Surveill; 2008 May; 13(21):. PubMed ID: 18761968
    [No Abstract]   [Full Text] [Related]  

  • 15. Does hepatitis C virus really have no effect on survival in cases of infection with human immunodeficiency virus?
    Jenny-Avital ER
    Clin Infect Dis; 2000 Feb; 30(2):409-10. PubMed ID: 10671362
    [No Abstract]   [Full Text] [Related]  

  • 16. Hepatitis C virus seroprevalence: selected health care settings in Texas.
    Melville SK; Heseltine G; Delamater E; Gilani Z; Hendricks K; Suarez L
    Tex Med; 2006 Mar; 102(3):56-61. PubMed ID: 17115588
    [No Abstract]   [Full Text] [Related]  

  • 17. Need-adapted HCV-treatment setting for injection drug users.
    Reimer J; Haasen C
    Lancet; 2009 Jun; 373(9681):2090-1. PubMed ID: 19376573
    [No Abstract]   [Full Text] [Related]  

  • 18. Ending the mass criminalisation of people who use drugs: a necessary component of the public health response to hepatitis C.
    Ford C; Bressan J
    BMC Infect Dis; 2014; 14 Suppl 6(Suppl 6):S4. PubMed ID: 25253223
    [No Abstract]   [Full Text] [Related]  

  • 19. Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users.
    Edlin BR; Kresina TF; Raymond DB; Carden MR; Gourevitch MN; Rich JD; Cheever LW; Cargill VA
    Clin Infect Dis; 2005 Apr; 40 Suppl 5(Suppl 5):S276-85. PubMed ID: 15768335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Co-morbidity of infectious and addictive diseases in St. Petersburg and the Leningrad Region, Russia.
    Krupitsky EM; Zvartau EE; Lioznov DA; Tsoy MV; Egorova VY; Belyaeva TV; Antonova TV; Brazhenko NA; Zagdyn ZM; Verbitskaya EV; Zorina Y; Karandashova GF; Slavina TY; Grinenko AY; Samet JH; Woody GE
    Eur Addict Res; 2006; 12(1):12-9. PubMed ID: 16352898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.